Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Orphan Reach, a company headquartered in the United Kingdom with offices in Ireland, Germany, India, Canada, and the U.S. Started nearly 20 years ago, Orphan Reach is a CRO dedicated to clinical research in rare diseases. This is Emmes’ second acquisition in the past four months, following the acquisition of Neox s.r.o., an EU-based CRO, in December 2020.
Read the full article: Emmes Announces Acquisition of UK-Based Orphan Reach //
Source: https://www.prnewswire.com/news-releases/emmes-announces-acquisition-of-uk-based-orphan-reach-301289412.html